Spero Therapeutics Inc (SPRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Spero Therapeutics Inc (SPRO) has a cash flow conversion efficiency ratio of -0.141x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.35 Million) by net assets ($59.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Spero Therapeutics Inc (SPRO) net asset quality to measure how much of total assets are equity-financed.
Spero Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Spero Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Spero Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
Spero Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Spero Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Formosa Electronic Industries
TWO:8171
|
-0.016x |
|
Apex Science & Engineering Corp
TW:3052
|
0.515x |
|
Seronics Co. Ltd
KQ:042600
|
-0.029x |
|
Se Gyung Hi Tech Co.Ltd
KQ:148150
|
0.004x |
|
SG&G Corporation
KQ:040610
|
0.002x |
|
Grupo Greening 2022 SA
MC:GGR
|
N/A |
|
Wittchen SA
WAR:WTN
|
0.113x |
|
Outset Medical Inc
NASDAQ:OM
|
-0.115x |
Annual Cash Flow Conversion Efficiency for Spero Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Spero Therapeutics Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Spero Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $59.02 Million | $-12.62 Million | -0.214x | +57.92% |
| 2024-12-31 | $46.12 Million | $-23.44 Million | -0.508x | -64.67% |
| 2023-12-31 | $106.89 Million | $-32.99 Million | -0.309x | -203.18% |
| 2022-12-31 | $75.93 Million | $-7.73 Million | -0.102x | +86.03% |
| 2021-12-31 | $88.29 Million | $-64.35 Million | -0.729x | -12.07% |
| 2020-12-31 | $132.04 Million | $-85.87 Million | -0.650x | +3.04% |
| 2019-12-31 | $74.57 Million | $-50.02 Million | -0.671x | -96.11% |
| 2018-12-31 | $115.86 Million | $-39.62 Million | -0.342x | +25.71% |
| 2017-12-31 | $84.96 Million | $-39.11 Million | -0.460x | +89.89% |
| 2016-12-31 | $6.36 Million | $-28.96 Million | -4.553x | -112.18% |
| 2015-12-31 | $-257.00K | $-9.61 Million | 37.385x | -- |
About Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including … Read more